55.03
price down icon1.27%   -0.71
after-market Dopo l'orario di chiusura: 56.13 1.10 +2.00%
loading
Precedente Chiudi:
$55.74
Aprire:
$55.63
Volume 24 ore:
382.56K
Relative Volume:
0.76
Capitalizzazione di mercato:
$3.49B
Reddito:
-
Utile/perdita netta:
$-145.21M
Rapporto P/E:
-23.93
EPS:
-2.3
Flusso di cassa netto:
$-140.12M
1 W Prestazione:
+1.57%
1M Prestazione:
+20.26%
6M Prestazione:
+20.42%
1 anno Prestazione:
+20.73%
Intervallo 1D:
Value
$54.87
$56.58
Intervallo di 1 settimana:
Value
$52.65
$57.45
Portata 52W:
Value
$31.42
$58.26

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Nome
Moonlake Immunotherapeutics
Name
Telefono
41 41 510 8022
Name
Indirizzo
DORFSTRASSE 29, ZUG
Name
Dipendente
100
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
MLTX's Discussions on Twitter

Confronta MLTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
55.03 3.54B 0 -145.21M -140.12M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-19 Aggiornamento Wolfe Research Peer Perform → Outperform
2025-03-18 Iniziato RBC Capital Mkts Outperform
2025-01-17 Aggiornamento Goldman Neutral → Buy
2024-11-05 Ripresa Wedbush Outperform
2024-08-26 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-25 Iniziato Oppenheimer Outperform
2024-04-02 Iniziato Goldman Neutral
2024-02-15 Iniziato Wolfe Research Outperform
2023-12-08 Iniziato Citigroup Buy
2023-11-02 Iniziato Stifel Buy
2023-09-14 Downgrade Bryan Garnier Buy → Neutral
2023-08-31 Iniziato Needham Buy
2023-06-15 Iniziato Barclays Equal Weight
2023-05-01 Iniziato Guggenheim Buy
2023-03-22 Iniziato Wedbush Outperform
2023-03-09 Iniziato BTIG Research Buy
2023-02-14 Iniziato Cantor Fitzgerald Overweight
2023-02-02 Iniziato Bryan Garnier Buy
2022-11-11 Iniziato Jefferies Buy
2022-08-25 Iniziato SVB Leerink Outperform
2022-07-21 Iniziato H.C. Wainwright Buy
2022-07-07 Iniziato Cowen Outperform
Mostra tutto

Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie

pulisher
Jul 23, 2025

MoonLake Immunotherapeutics Stock Analysis and ForecastUnprecedented market success - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about MoonLake Immunotherapeutics stockTurbocharged investment results - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal - insights.citeline.com

Jul 23, 2025
pulisher
Jul 23, 2025

MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

What drives MoonLake Immunotherapeutics stock priceExplosive capital gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is MoonLake Immunotherapeutics a good long term investmentSky-high return potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 17, 2025

(MLTX) Trading Advice - news.stocktradersdaily.com

Jul 17, 2025
pulisher
Jul 17, 2025

MoonLake Immunotherap Scores Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily

Jul 17, 2025
pulisher
Jul 15, 2025

What makes MoonLake Immunotherapeutics stock price move sharplyFree Investment Risk Control - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why MoonLake Immunotherapeutics stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How MoonLake Immunotherapeutics stock performs during market volatilityQuick Profit Idea Stream - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

MoonLake Immunotherap Reaches 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily

Jul 15, 2025
pulisher
Jul 10, 2025

Merck made $3B+ offer for MoonLake earlier this yearreport - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

MoonLake Immunotherap Getting Closer To Key Technical Benchmark - Investor's Business Daily

Jul 10, 2025
pulisher
Jul 07, 2025

MoonLake Immunotherapeutics Director Makes a Major Stock Move! - TipRanks

Jul 07, 2025
pulisher
Jun 28, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Challenges - geneonline.com

Jun 28, 2025
pulisher
Jun 19, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Sector Challenges - geneonline.com

Jun 19, 2025
pulisher
Jun 16, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Developments - geneonline.com

Jun 16, 2025
pulisher
Jun 15, 2025

Learn to Evaluate (MLTX) using the Charts - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 15, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Industry Developments - geneonline.com

Jun 15, 2025
pulisher
Jun 13, 2025

MoonLake Immunotherapeutics’ SWOT analysis: nanobody firm’s stock poised for pivotal phase III data - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Merck's Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

IIH interview: Matthias Bodenstedt discusses MoonLake’s capital raising journey, the appeal of SLK and plans for the future - Investors in Healthcare

Jun 13, 2025
pulisher
Jun 13, 2025

MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating - TipRanks

Jun 13, 2025
pulisher
Jun 12, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Focus on Inflammatory Disease Treatments - geneonline.com

Jun 12, 2025
pulisher
Jun 10, 2025

MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Merck Offers Over $3 Billion to Acquire MoonLake Immunotherapeutics Amid Biotech Sector Focus - geneonline.com

Jun 10, 2025
pulisher
Jun 09, 2025

MoonLake Immunotherapeutics (MLTX) Hosts Investor Meetings Amid Merger Speculation | MLTX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics - TipRanks

Jun 09, 2025

Moonlake Immunotherapeutics Azioni (MLTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):